November 2016

Contents

Editorial

• November/December 2016: Volume 17 Number 11/12

Supplements

• UK Guide to PrEP (2nd Edition)

Conference reports

• International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016

• 1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs

• Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses

• Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients

• Once-weekly albuvirtide infusion: early results of T-20-like compound

• Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

• Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

• Further reports of CNS-related side effects with dolutegravir

• Generic PrEP bought online for UK use is validated by drug testing service

• Immunology and HIV persistence – implications for a cure

• Selected webcasts from Glasgow 2016

• 2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago

• A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options

• Second case of drug resistant HIV infection in person adherent on PrEP

• TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

• Potential for EFdA as PrEP to prevent HIV transmission in women and their infants

• Antibody therapy leads to sustained post-treatment SIV control in macaques

Antiretrovirals

• FDA approves maraviroc for children aged two and older

• Ibalizumab infusion reduces viral load in people with HIV multi-drug resistance

• GSK discontinues development of maturation inhibitor BMS-955176

Treatment access

• CHAI’s ARV market report shows more people than ever on ART in 2015 – and on better ART: but still some way to go

• New online database for patent expiry dates in low- and middle-income countries

• Global Fund is $2.6 billion short for 2017-2019: only $10.3 rather than 12.9 billion is available

Pregnancy

• Dolutegravir use in a London cohort – including nine pregnant women

• HIV positive and HIV negative pregnancies in the UK and Ireland have similar outcomes including for older women: impressive 15-year review

Guidelines

• Factsheets for switching to Rezolsta (darunavir/c) or Evotaz (atazanavir/c)

• EACS Guidelines updated (October 2016)

• Swedish guidelines updated (November 2016)

Hepatitis coinfection

• Tenofovir alafenamide (TAF) approved in US to treat hepatitis B with EU set to follow

HIV prevention and transmission

• UK 2015 HIV statistics: high engagement with ART but new infections in gay men and late diagnosis overall still high

• NHS England had no legal basis to delay PrEP: Court of Appeal upholds judgement

• NICE evidence review supports efficacy of Truvada as PrEP in the UK

On the web

• Conference materials online

PDFs

• November/December 2016: Volume 17 Number 11/12